Roche: Matthew Sause
Roche Diagnostics has named Matthew Sause as president and CEO, North America, effective Nov. 4. He replaces Jack Phillips, who left Roche at the end of August. Sause was previously the senior VP and head of global commercial product strategy at Gilead Sciences. From 2002 to 2014, Sause worked in the diagnostics division at Roche, filling US-based sales roles in molecular diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In 2014, Sause moved to the pharmaceuticals division, where he was president of country operations in Peru and South Korea, before becoming VP and lifecycle leader for Roche's cancer drug Tecentriq.
Tempus: Scott Gottlieb
Tempus has named former US Food and Drug Administration Commissioner Scott Gottlieb to its board of directors. Gottlieb headed the FDA from May 2017 until April 2019. In the 2000s, he was the agency's deputy commissioner for medical and scientific affairs and later a senior advisor to the former FDA Commissioner. An internal medicine physician, Gottlieb also had a stint as senior advisor to the administrator for the centers for Medicare and Medicaid Services, where he helped implement the Medicare Part D drug benefit. He also spent 10 years as a venture capitalist with New Enterprise Associates. He remains a resident fellow of the American Enterprise Institute, a conservative think tank.
NanoString: Don Kania
NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.
Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.